CANCER:

Pancreatic Cancer

Related cancers:

‹

Pancreatic Ductal Adenocarcinoma (61)

Pancreatic Adenocarcinoma (43)

Pancreatic Ductal Adenocarcinoma (61)

Pancreatic Adenocarcinoma (43)

›

GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C3 – Early Trials Sci Rep - 1 week
BRCA2 mutation BRCA2 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	GEM-CAP Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	LV5FU2 Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	CAPOX Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	5-fluorouracil + nanoliposomal irinotecan Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	5-fluorouracil + irinotecan Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	entrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	erlotinib Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	5-fluorouracil + capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine + capecitabine Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline
PALB2 mutation PALB2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	FOLFIRINOX Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Pancreatic Cancer Pancreatic Cancer	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Pancreatic Cancer Pancreatic Cancer	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Pancreatic Cancer Pancreatic Cancer	entrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Pancreatic Cancer Pancreatic Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Pancreatic Cancer Pancreatic Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Pancreatic Cancer Pancreatic Cancer	larotrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	5-fluorouracil + irinotecan Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	entrectinib Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	entrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	FG-3019 Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	capecitabine Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	devimistat Sensitive: B - Late Trials
TMB-H TMB-H	Pancreatic Cancer Pancreatic Cancer	pembrolizumab Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	SBP-101 Sensitive: B - Late Trials
TMB-H TMB-H	Pancreatic Cancer Pancreatic Cancer	PD1 inhibitor Sensitive: B - Late Trials
ELAVL1 expression ELAVL1 expression	Pancreatic Cancer Pancreatic Cancer	NUC-3373 Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine + capecitabine Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	GEM-CAP + FOLFIRINOX Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	TH 302 Sensitive: B - Late Trials
CCL11 overexpression CCL11 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	tertomotide Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	CORT125134 Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CEND-1 Sensitive: B - Late Trials
RET fusion RET fusion	Pancreatic Cancer Pancreatic Cancer	pralsetinib Sensitive: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Pancreatic Cancer Pancreatic Cancer	rucaparib Sensitive: C1 - Off-label
NTRK1 fusion NTRK1 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	larotrectinib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	rucaparib Sensitive: C1 - Off-label
KRAS G12C KRAS G12C	Pancreatic Cancer Pancreatic Cancer	sotorasib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Pancreatic Cancer Pancreatic Cancer	encorafenib + binimetinib Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Pancreatic Cancer Pancreatic Cancer	pembrolizumab Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Pancreatic Cancer Pancreatic Cancer	vemurafenib Sensitive: C1 - Off-label
HER-2 overexpression HER-2 overexpression	Pancreatic Cancer Pancreatic Cancer	trastuzumab Sensitive: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label
ATM mutation ATM mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: C1 - Off-label
ATM mutation ATM mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label
RET fusion RET fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	pralsetinib Sensitive: C1 - Off-label
TMB-H TMB-H	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	pembrolizumab Sensitive: C1 - Off-label
RET fusion RET fusion	Pancreatic Cancer Pancreatic Cancer	selpercatinib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Pancreatic Cancer Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	rucaparib Sensitive: C2 – Inclusion Criteria
NRAS mutation NRAS mutation	Pancreatic Cancer Pancreatic Cancer	avelumab Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Pancreatic Cancer Pancreatic Cancer	avelumab Sensitive: C2 – Inclusion Criteria
NRG1 fusion NRG1 fusion	Pancreatic Cancer Pancreatic Cancer	MCLA-128 Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria
TP53 mutation TP53 mutation	Pancreatic Cancer Pancreatic Cancer	gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
HGF-H HGF-H	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ipilimumab Sensitive: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C3 – Early Trials
KRAS G12R KRAS G12R	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	selumetinib Sensitive: C3 – Early Trials
UGT1A128 + UGT1A16 UGT1A128 + UGT1A16	Pancreatic Cancer Pancreatic Cancer	FOLFIRINOX Sensitive: C3 – Early Trials
KRAS exon 2 mutation KRAS exon 2 mutation	Pancreatic Cancer Pancreatic Cancer	erlotinib Resistant: C3 – Early Trials
EPHB4 expression EPHB4 expression	Pancreatic Cancer Pancreatic Cancer	gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
KRAS G12R KRAS G12R	Pancreatic Cancer Pancreatic Cancer	cobimetinib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	trametinib Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA1 mutation + BRCA2 mutation BRCA1 mutation + BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
FANCF mutation FANCF mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
MSH2 mutation MSH2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials

Pancreatic Cancer

Associations(278)

Associations
(278)